|Application ||WB, IHC-P, IF, IP|
|Predicted||Human, Mouse, Rat|
|Calculated MW||43696 Da|
|Dilution||IF (1:20 - 1:50), IHC-P (1:100), IP (1:20 - 1:50), WB (1:500 - 1:2000)|
|Other Names||IRF9, Interferon regulatory factor 9, ISGF3 p48 subunit, ISGF3G, p48, IRF-9, ISGF3, ISGF-3 gamma|
|Target/Specificity||Human ISGF3 / IRF9|
|Reconstitution & Storage||Affinity purified|
|Precautions||Anti-ISGF3 / IRF9 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Transcription factor that mediates signaling by type I IFNs (IFN-alpha and IFN-beta). Following type I IFN binding to cell surface receptors, Jak kinases (TYK2 and JAK1) are activated, leading to tyrosine phosphorylation of STAT1 and STAT2. IRF9/ISGF3G associates with the phosphorylated STAT1:STAT2 dimer to form a complex termed ISGF3 transcription factor, that enters the nucleus. ISGF3 binds to the IFN stimulated response element (ISRE) to activate the transcription of interferon stimulated genes, which drive the cell in an antiviral state.|
|Cellular Location||Cytoplasm. Nucleus. Note=Translocated into the nucleus upon activation by IFN-alpha/beta|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.